Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis

作者：Paul Krogstad, Pearl Samson, Edward P. Acosta, Jack Moye, Ellen Townley, Sarah Bradford, Emily Brown, Kayla Denson, Bobbie Graham, Laura Hovind, Thucuma Sise, Hedy Teppler, Sisinyana Ruth Mathiba, Lee Fairlie, Jana Winckler, Gretchen Slade, Tammy Meyers · 发表于：Journal of the Pediatric Infectious Diseases Society · 年份：2020 · DOI：10.1093/jpids/piaa039 · 被引用次数：9 · 研究领域：HIV/AIDS drug development and treatment、Pharmacological Effects and Toxicity Studies、Pharmaceutical studies and practices

Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. CLINICAL TRIALS REGISTRATION: NCT01751568.